A comprehensive view of vaccination / immunization. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Moderna reports early progress in vaccines for Epstein-Barr virus, norovirus and shingles during its vaccines day; Moderna reports vaccine candidates show stronger immune responses and generally well-tolerated results in early clinical trials
Published:
March 27, 2024
by FierceBiotech
|
Moderna initiates final phase of trials for four vaccines against latent infections, including chickenpox and shingles, and norovirus responsible for gastroenteritis; the company also developing a new-generation COVID-19 vaccine
Published:
March 27, 2024
by CE Noticias Financieras (Latin America)
|
IR Insights: Recapping our Fifth Annual Vaccines Day
Published:
March 27, 2024
by Moderna Inc.
|
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published:
March 27, 2024
by Moderna Inc.
|
Moderna's next-generation COVID-19 vaccine, mRNA-1283, shows a higher immune response against SARS-CoV-2 in Phase 3 trial compared to the company's currently vaccine; the new vaccine also has potential for longer shelf life and storage benefits
Published:
March 26, 2024
by Moderna Inc.
|
Ask us about our Health Care Sector market view